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Abstract
Background: To investigate age-related severity, patterns of retinal structural damage, and functional visual
recovery in pediatric and adult cohorts of myelin oligodendrocyte glycoprotein antibody-associated disease
(MOGAD) optic neuritis (ON).
Methods: All MOGAD patients from the 5 participating centers were included. Patients with initial manifestation <
18 years were included in the pediatric (MOGADped) cohort and patients with ≥18 years in the adult (MOGADadult)
cohort. For patients with MOGAD ON, examinations at least ≥6 months after ON onset were included in the
analyses. Using spectral domain optical coherence tomography (SD-OCT), we acquired peripapillary retinal nerve
fiber layer thickness (pRNFL) and volumes of combined ganglion cell and inner plexiform layer (GCIPL). High- and
2.5% low-contrast visual acuity (HCVA, LCVA) and visual-evoked potentials (VEP) were obtained.
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Results: Twenty MOGADped (10.3±3.7 years, 30 MOGAD ON eyes) and 39 MOGADadult (34.9±11.6 years, 42 MOGAD
ON eyes) patients were included. The average number of ON episodes per ON eye was similar in both groups (1.8±
1.3 and 2.0±1.7). In both pediatric and adult MOGAD, ON led to pronounced neuroaxonal retinal atrophy (pRNFL:
63.1±18.7 and 64.3±22.9 μm; GCIPL: 0.42±0.09 and 0.44±0.13 mm3, respectively) and moderate delay of the VEP
latencies (117.9±10.7 and 118.0±14.5 ms). In contrast, visual acuity was substantially better in children (HCVA: 51.4±
9.3 vs. 35.0±20.6 raw letters, p=0.001; LCVA: 22.8±14.6 vs. 13.5±16.4, p=0.028). Complete visual recovery (HCVA-
logMAR 0.0) occurred in 73.3% of MOGADped and 31% MOGADadults ON eyes, while 3.3% and 31% demonstrated
moderate to severe (logMAR > 0.5) visual impairment. Independent of retinal atrophy, age at ON onset significantly
correlated with visual outcome.
Conclusion: Pediatric MOGAD ON showed better visual recovery than adult MOGAD ON despite profound and
almost identical neuroaxonal retinal atrophy. Age-related cortical neuroplasticity may account for the substantial
discrepancy between structural changes and functional outcomes.
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Introduction
Myelin oligodendrocyte glycoprotein antibody-associated
disease (MOGAD) is a newly defined autoimmune dis-
order of the central nervous system (CNS) [1]. While
immune responses targeting myelin oligodendrocyte
glycoprotein (MOG) have been extensively studied in ex-
perimental autoimmune encephalomyelitis [1], the clin-
ical relevance of MOG-immunoglobulin (Ig)G was only
recently appreciated following the identification of auto-
antibodies targeting conformational epitopes of full-
length MOG in humans [2]. MOGAD patients may de-
velop any combination of monophasic or relapsing acute
disseminated encephalomyelitis (ADEM), non-ADEM
encephalitis, neuromyelitis optica spectrum disorder
(NMOSD), optic neuritis (ON), transverse myelitis
(TM), brainstem encephalitis, or rarely multiple sclerosis
(MS)-like demyelinating disease [3–5]. Clinical manifes-
tations seem to be age-dependent: children < 10 years
are more likely to develop an ADEM phenotype, while
those ≥10 years are more likely to present with an
NMOSD- or MS-like phenotype similar to adults [6]. In
both pediatric and adult patients, isolated, bilateral, or
recurrent ON are common clinical presentations [3, 5, 7,
8]. High levels of MOG expression and enhanced blood-
brain barrier permeability in the optic nerve may explain
its frequent involvement [9, 10]. Although the histopath-
ology of cerebral lesions in MOGAD patients demon-
strates relative preservation of axonal structures, severe
visual impairment or functional blindness have been re-
ported in >30% of MOGADadults ON patients, and OCT
studies repeatedly demonstrated profound axonal degen-
eration with loss of retinal ganglion cells [11–14]. Al-
though MOG-IgG antibodies have been frequently
reported in children with ON, there are only a few stud-
ies investigating retinal changes and visual outcomes in
this population [5, 15–17]. Moreover, there are no stud-
ies comparing ON course and outcome in children and
adults with MOGAD. The latter is especially interesting
as pediatric MS and MOGAD patients generally demon-
strate better relapse recovery than adults [18–22]. Here,
we compared the outcomes of MOGADped and MOGA-
Dadult ON including age-related (1) severity and patterns




We conducted an analysis of prospectively collected data
from MOGADped and MOGADadult patients with or
without ON. The inclusion criteria included the acute
presentation of demyelinating disease, MOG-IgG sero-
positivity, availability of OCT, visual acuity data, and
clinical information. If one or multiple ON events were
known, visits could be considered at least 6 months after
the last ON. During the study period (2018–2020), all
patients tested positive for MOG-IgG were included
who met the inclusion criteria and who were seen at five
academic university centers specialized in neuroimmu-
nological diseases (Department of Pediatric Neurology,
Children’s Hospital Datteln, University Witten/Her-
decke, Germany, N=9; Department of Neuropediatrics
and Social Pediatrics University Hospital of Pediatrics
and Adolescent Medicine, Ruhr-University Bochum, N=
3; Neurology Department, St. Josef Hospital Bochum,
Bochum, Germany, N=16; Institute of Clinical Neuroim-
munology, LMU Hospital, Munich, Germany, N=29, and
Institute of Pediatrics, University Hospital Vall d’Heb-
ron, Barcelona, Spain, N=2) [total N=59]. Five patients
were excluded due to incomplete examination data (n=
2) or an acute ON at the time of examination (n=3) (see
supplementary Figure 3). A part of the MOGAD cohort
of the Institute of Clinical Neuroimmunology (13/29 pa-
tients) has already been published as a subset of other
cohort analyses [12, 13]. Written informed consent was
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obtained from all patients participating in the study. The
local ethics committees approved the study protocol in
accordance with the Declaration of Helsinki (1964) in its
currently applicable version. Two groups of patients
were evaluated depending on the age at disease mani-
festation: group 1 with 20 MOG-IgG-positive children
with initial manifestation < 18 years (MOGADped) and
group 2 with 39 MOG-IgG-positive adult patients with
initial manifestation ≥ 18 years (MOGADadult). Demo-
graphic (gender and age at initial manifestation) and
clinical (disease duration, number and side of clinical
ON episodes) data were collected for all patients. For
the detection of MOG-IgG, serum samples were ana-
lyzed during the initial workup at least once by estab-
lished cell-based assays at the discretion of each center
using the laboratory’s cutoffs (MOG IFT, EUROIM-
MUN, Laboratory Stöcker, Germany; Reindl Lab, Med-
ical University of Innsbruck, Innsbruck, Austria; Meinl
Lab, LMU Hospital, Munich, Germany) [1, 2, 23].
Optical coherence tomography (OCT) and visual acuity
All centers used spectral-domain optical coherence tom-
ography (SD-OCT, SPECTRALIS, Heidelberg Engineer-
ing, Heidelberg, Germany) with automatic real-time
(ART) averaging. A scan around the optic nerve with an
activated eye tracker (12°, 3.5 mm ring, 50≤ ART ≤100)
and a macular volume scan (20° × 20°, 25 vertical B-scans,
20 ≤ ART ≤ 49) were performed as cylinders of 3 mm
diameter around the fovea based on local protocols. The
thickness of the peripapillary retinal nerve fiber layer
(pRNFL) and the volumes of the macular retinal nerve
fiber (mRNFL), the combined ganglion cell and inner
plexiform layer (GCIPL), the inner nuclear layer (INL), the
combined outer plexiform layer and outer nuclear layer
(OPONL), and the total macular volume (TMV) were
analyzed. The segmentation of all layers was performed
semi-automatically using software from the SD-OCT
manufacturer (Eye Explorer 1.9.10.0 with viewing module
6.3.4.0, Heidelberg Engineering, Heidelberg, Germany).
Experienced evaluators carefully checked all scans for suf-
ficient quality and segmentation errors and corrected
them if necessary. The SD-OCT data in this study are ana-
lyzed and reported according to the recommendations of
APOSTEL and OSCAR-IB [24, 25].
In addition, at the time of OCT examination, habit-
ually corrected high-contrast and low-contrast monocu-
lar visual acuity (VA) was acquired using high contrast
and 2.5% low-contrast Sloan letter charts placed in a
retro-illuminated light box at 2 m distance. Each chart
consists of 14 lines with 5 letters per line that are stan-
dardized with equal difficulty per line and equal spacing
between the lines. The total number of correct letters
identified on each chart was tested to determine high-
and low-contrast VA (HCVA, LCVA; maximum, 70
letters). Characteristic pRNFL scans in a pediatric and
an adult MOGAD patient are shown in Fig. 1.
Visual evoked potentials (VEP)
VEP data (Keypoint.net, Neurolite Software, Natus,
Switzerland) were collected from occipital midline re-
ferred to a mid-frontal electrode according to the Inter-
national Society for Clinical Electrophysiology of Vision
standards. Pattern reversal VEP was produced by high-
contrast, black and white checks. Each check has the size
of 171.6 arc minute. The examination was performed in
a dark room in a 1-m distance. P100 latency and the
P100-P125 amplitude were collected. All VEP examina-
tions were performed in Bochum (data available for 15
MOGADped and 12 MOGADadult patients).
Statistical methods
Clinical data, OCT, VEP, and VA results were compared
between MOGADped and MOGADadult patients. The
mean and standard deviation were calculated for continu-
ous variables, frequency, and proportion for categorical
variables. The non-parametric Mann-Whitney U test and
chi-square test were used to compare two independent
groups. Statistical significance was defined as p < 0.05.
SD-OCT data, VEP data, and HCVA/LCVA in the
eyes with and without ON were analyzed within and be-
tween the MOGADped and MOGADadult cohorts using
generalized estimating equation models (GEE) to ac-
count for within-patient inter-eye correlation. The cor-
relation matrix parameter was set to “exchangeable.”
Further, we performed a Spearman correlation to iden-
tify the possible factors determining the visual outcome
in MOGAD ON. Age at ON, number of ON episodes
per eye, the extent of retinal degeneration (pRNFL and
GCIPL thickness), and VEP P100 latency were included
in the analysis. For cases of recurrent ON, we calculated
an average age at ON onset. Due to a relatively small
sample size, both groups were pooled. All factors that
significantly correlated with visual outcome were in-
cluded in GEE analysis. Data were analyzed with SPSS
version 26 (IBM SPSS Statistics).
Results
Cohort description
We enrolled 20 MOG-IgG-positive children
(MOGADped patients, female:male 13:7, mean age 10.3±
3.7 years) and 39 MOG-IgG-positive adults (MOGADa-
dult patients, female: male 20:19, mean age 34.9±11.6
years). From the medical history, 2 patients had no ON,
6 had unilateral ON, and 12 had bilateral ON in the
MOGADped patient cohort (total 30 ON affected eyes).
Accordingly, in the MOGADadult patient cohort, 15 had
no ON, 6 had unilateral ON, and 18 had bilateral ON
(total 42 ON affected eyes). The main clinical data of all
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patients are described in Table 1. Eight of 20 MOG-IgG-
positive children were diagnosed with recurrent
NMOSD, 6 children with recurrent ON (rON), 3 chil-
dren with ADEM + rON, and 3 children with encephalo-
myelitis. Three of 39 MOG-IgG-positive adults were
diagnosed with monophasic NMOSD, 12 with recurrent
NMOSD, 14 with encephalomyelitis, 9 adults with rON,
and 1 adult with ADEM. There were no differences in
gender, disease duration, or number of previous ON epi-
sodes between the two groups. Eighteen (94.7%) of the
MOGADped patients were on long-term immunotherapy
at the time of SD-OCT (8 monotherapy with oral pred-
nisone, 5 intravenous long-term immunoglobulin/sub-
cutaneous immunoglobulin (IVIG/SCIG), 3 glatiramer
acetate, 1 rituximab, 1 azathioprine, 1 oral prednisone as
an add-on therapy) compared with 30 (76.9%) of
MOGADadult patients (12 azathioprine, 7 rituximab, 1 oral
prednisone as an add-on therapy, 3 methotrexate, 2 toci-
lizumab, 2 teriflunomide, 2 glatiramer acetate, 1 monother-
apy with oral prednisone, and 1 long-term IVIG).
Pediatric and adult MOGAD ON cause profound
neuroaxonal retinal atrophy
The main SD-OCT results are shown in Table 2 (for
more detailed results, see supplementary Table 3 and
supplementary Figure 4). The thickness of pRNFL was
significantly reduced in MOGADped- and MOGADadult-
ON eyes compared to non-ON eyes globally as well as
in all segments (pRNFL S, pRNFL I, pRNFL T, pRNFL
N, pRNFL PMB); the pRNFL N/T ratio remained un-
changed (see Fig. 1 for illustrating OCT images). The
total macular volume (TMV), as well as combined GCIP
Fig. 1 Representative pediatric and adult retinal OCT scans after recurrent MOGAD-ON. Despite almost identical neuroaxonal retinal atrophy,
functional vision is notably better in children than adults. Abbreviations: OD oculus dexter, G global pRNFL, N nasal pRNFL, I inferior pRNFL, T
temporal pRNFL, PMB paillo-macular-bundle, TMV total macular volume, GCIPL combined ganglion cell and inner plexiform layer
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L volume, were also significantly decreased in ON eyes
of both pediatric and adult patients compared to non-
ON eyes. In contrast, the volume of the inner nuclear
layer (INL) was increased in ON eyes of both groups.
Comparing MOGADped-ON and MOGADadult-ON
eyes, we found no differences in pRNFL thickness or
volumes of the macular GCIPL, INL, and OPONL, while
macular RNFL was significantly lower in MOGADped-
ON eyes compared to MOGADadult-ON eyes. Macular
microcysts were observed in 10% of MOGADped-ON
and 7.7% of MOGADadult-ON eyes.
Peripapillary retinal atrophy patterns are similar
independently of age
There was no difference in the pattern of neuroaxonal
retinal atrophy between MOGADped and MOGADadult
ON eyes (Table 3, supplementary results). MOGAD ON
eyes showed no temporal predominance of pRNFL
Table 1 Demographic and main clinical characteristics of pediatric and adult cohorts
MOGADped (n=20) MOGADadult (n=39) p
Age at initial manifestation, median (range) 10.5 (4–15) 35.0 (19–64) <0.001
Females, n (%) 13 (65.0%) 20 (51.3%) 0.157
Ethnicity 20 Caucasians 36 Caucasians
3 Asians
0.081
Disease duration (years), median (range) 4.5 (0–22) 6.5 (0–24) 0.084
Patients with a clinical history of ON, n (%) 18 (90.0%) 24 (61.5%) 0.001
Patients with unilateral ON, n (%) 6 (30.0%) 6 (15.4%) 0.062
Patients with bilateral ON, n (%) 12 (60.0%) 18 (46.2%) 0.154
Patients with a simultaneous bilateral ON, n (%) 8 (40.0%) 14 (35.9%) 0.663
Total ON eyes, n (%) 30 (75.0%) 42 (53.8%) 0.029
Number of ON episodes per eye, mean (SD) 1.8 (1.3) 2.0 (1.7) 0.864
Time between ON and examination in months, median (range) 7 (6–129) 10 (6–155) 0.2
Abbreviations: MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease, ON optic neuritis, SD standard deviation
Table 2 Comparison of OCT and VEP measures as well as visual acuity between MOGAD-ON and MOGAD-NON eyes in pediatric
and adult MOGAD patients






























pRNFL G 63.12 ± 18.74 90.30 ± 13.40 64.26 ± 22.85 96.64 ± 20.67 < 0.001 0.001 0.997 0.292
TMV 2.19 ± 0.11 2.30 ± 0.13 2.22 ± 0.12 2.31 ± 0.11 0.021 0.048 0.484 0.718
mRNFL 0.12 ± 0.02 0.14 ± 0.01 0.13 ± 0.02 0.14 ± 0.03 < 0.001 0.537 0.012 0.278
mGCIPL 0.42 ± 0.09 0.57 ± 0.08 0.44 ± 0.13 0.57 ± 0.08 < 0.001 0.012 0.555 0.853
mINL 0.28 ± 0.03 0.26 ± 0.02 0.29 ± 0.04 0.26 ± 0.02 0.001 0.017 0.793 0.994
mOPONL 0.77 ± 0.07 0.74 ± 0.08 0.77 ± 0.05 0.75 ± 0.05 0.307 0.949 0.779 0.589
VEP P100
latency
117.86 ± 10.67 112.44 ± 9.59 117.99 ± 14.51 118.15 ± 9.84 0.324 0.790 0.946 0.115
VEP
amplitude
10.57 ± 6.12 8.52 ± 4.47 5.76 ± 2.79 7.61 ± 5.21 0.235 0.049 – –
HC VA 51.36 ± 9.33 55.60 ± 8.88 34.97 ± 20.57 52.03 ± 8.67 0.245 0.002 < 0.0001 0.325
2.5% LC VA 22.83 ± 14.62 25.60 ± 13.94 13.54 ± 16.44 29.52 ± 13.89 0.963 0.017 0.028 0.451
GEE analysis: p value: significant results p < 0.05 are indicated in bold
Abbreviations: MOGAD-ON eyes with a history of ON, MOGAD-NON eyes without a history of ON, pRNFL peripapillary retinal nerve fiber layer (G global), TMV total
macular volume, mRNFL macular RNFL, mGCIPL macular ganglion cell and inner plexiform layer, mINL macular inner nuclear layer, mOPONL macular outer
plexiform and outer nuclear layer, HC high-contrast, LC low-contrast, VA visual acuity, pRNFL thickness in μm, macular volumes in mm3, VEP P100 latency in ms,
VEP amplitude in uV, VA number of correctly stated letters
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atrophy after 1.8±1.3 vs. 2.0±1.7 ON episodes per eye in
children and adults respectively. The N/T ratio was
comparable in affected eyes of pediatric and adult
patients.
Children demonstrate significantly better visual outcome
after MOGAD ON
VA testing revealed significantly worse HCVA and
LCVA in affected MOGADadult-ON eyes (Table 2, sup-
plementary Figure 4). This was not the case for affected
MOGADped-ON eyes. Complete visual recovery (defined
as HCVA logMAR 0.0) occurred in 73.3% of
MOGADped-ON eyes vs. 31.0% MOGADadult-ON eyes.
Only 3.3% of MOGADped-ON eyes vs. 31.0% of MOGA-
Dadult-ON eyes showed moderate to severe (HCVA log-
MAR > 0.5) visual impairment. HCVA and LCVA were
significantly worse in affected eyes of MOGADadult ver-
sus MOGADped patients; there was no difference noted
in unaffected non-ON eyes.
VEP are not different in affected eyes in pediatric and
adult MOGAD patients
VEP latencies were only moderately prolonged and
showed no significant differences between affected and
unaffected eyes in both cohorts (Table 2). Interestingly,
the VEP latencies were also almost identical in affected
eyes in MOGADped and MOGADadult patients. Signifi-
cant reduction of the VEP amplitudes was observed in
the affected eyes of MOGADadult patients only. VEP
amplitude varies with age and was not compared be-
tween MOGADped and MOGADadult patients.
Age at onset correlates with visual outcome in MOGAD
ON
We next evaluated the effects of the number of previous
ON attacks, age at ON onset, extent of neuroaxonal ret-
inal atrophy and optic nerve signal transmission (P100
latency) on the HCVA, and LCVA in the entire study
population (Fig. 2 and supplementary Figure 5). Neither
the number of previous ON nor P100 latency correlated
with HCVA or LCVA. Neuroaxonal retinal atrophy
weakly correlated with HCVA (rho=0.311 CI95% 0.080–
0.510, p=0.014 [pRNFL] and rho=0.282 CI95% 0.049–
0.486, p=0.036 [GCIPL]) and more closely with a LCVA
reduction (rho=0.498 CI95% 0.288 0.662, p<0.001
[pRNFL] and rho=0.448 CI95% 0.230 0.623, p=0.001
[GCIPL]) (Fig. 2). We observed a stronger correlation
with the age at ON onset (rho=−0.565 CI95% −0.713–
Fig. 2 Scatterplots of age at ON onset (a), pRNFL G thickness (b), and GCIPL volume (c) against visual outcome (HCVA and 2.5% LCVA). HCVA
correlated modestly with neuroaxonal retinal atrophy and more strongly with age at ON onset, whereas LCVA correlated moderately with
both parameters
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0.368, p<0.001 [HCVA] and rho=−0.460 CI95% −0.632–
0.244, p<0.001 [LCVA]).
Discussion
In this study, we were able to demonstrate a significantly
better visual recovery after ON in pediatric versus adult
MOGAD patients. Interestingly, substantial differences
in the functional outcome in these two groups were in-
dependent of structural neuroaxonal retinal atrophy and
signal transmission in the optic nerve, so that other age-
dependent mechanisms are likely to be responsible. Our
results thus add nicely to the recently published work on
clinical features and risk of relapse in children and adults
with MOGAD [22]. In this study, overall better remis-
sion of general relapses was reported in MOGADped
compared to MOGADadult patients, although the under-
lying mechanisms remained unclear [22].
On a structural level, we clearly observed both pRNFL
and GCIPL atrophy in the affected eye compared with
the unaffected eyes in MOGADped and MOGADadult pa-
tients, indicating combined neuroaxonal retinal atrophy.
The extent of degeneration was comparable across both
cohorts and in line with recent studies. Previously, we
and others have shown that pRNFL parameters, TMV,
mRNFL, mGCL, and mIPL are significantly reduced in
MOGADadult-ON eyes compared to healthy controls
[11–13]. There is little data on structural changes after
MOGAD ON in children. Two other groups have re-
ported significant neuroaxonal retinal atrophy following
MOGADped-ON with an average and median pRNFL
thickness of 68.7 ± 12.6 μm and 58 μm, respectively [26,
27]. These findings are comparable to our pRNFL mea-
sures (mean 63.1±18.7 μm). Data on GCIPL thickness
are only available from one Chinese cohort. Similar to
our study, the combined GCIPL volume in MOGADped-
ON was significantly reduced [26].
The volume of the INL was increased in ON eyes of
both MOGADped and MOGADadult patients. It has been
suggested that the INL may serve as a biomarker for in-
flammatory processes, since an increase in INL volume
is associated with MS-ON and risk for clinical relapse
[28]. However, the meaning of the INL volume change
in MOGAD remains uncertain and may occur in com-
pensation to neuroaxonal retinal atrophy. We could not
confirm an association between INL volume and relapse
rate in our cohort (data not shown). Microcystic macular
edema (MME) in the INL has been documented in
MOGAD ON [12, 13]. We observed INL-MME in 10%
vs. 7.7% of MOGADped- and MOGADadult-ON, but not
in unaffected eyes. In contrast to MS, we did not observe
predominant temporal atrophy or any other specific pat-
tern of RNFL loss. We found a high rate of RNFL atro-
phy in all optic nerve head segments [29].
MOGAD ON has been reported, in general, to have a
more favorable visual prognosis when compared to
AQP-4 IgG-seropositive NMOSD ON [30–35]. Study re-
sults, however, varied significantly, probably due in part
to MOGAD clinical heterogeneity [11, 12, 27, 30–32, 34,
36–38]. Our adult MOGAD cohort, being partly in-
cluded in previous multicenter studies, showed signifi-
cant visual impairment in a relatively high proportion of
patients after MOGAD ON [12, 13]. Nevertheless, other
studies also reported functional blindness in MOGAD
ON patients, with a VA below logMAR 1.0 in 13% of
MOGAD ON eyes [11, 13]. In contrast, we observed a
very good functional recovery in the pediatric cohort
despite similar levels of neuroaxonal retinal atrophy.
Interestingly, another study also demonstrated a more
favorable functional outcome in MOGAD ON compared
to AQP4-IgG seropositive NMOSD ON despite similar
structural pRNFL degeneration [37]. HCVA in our
MOGADped-ON cohort was similar to that reported by
Wan et al. (complete recovery in 85% of affected eyes
[n=59, mean age 12.6, range 3.9–18.8]) [36]. In contrast,
Eyre et al. showed that only 65% of children from the
mixed cohort recovered completely; microstructural
damage of the retina was the only factor correlating with
visual recovery [38].
The association of better visual recovery with younger
age at ON onset is a central finding of this study. The
better visual recovery in younger patients was independ-
ent of the number of previous ON attacks per eye,
microstructural retinal changes, or optic nerve signal
transmission. This is generally consistent with previous
observations of better visual recovery in younger patients
with AQP4-abs-positive NMOSD-ON and MS-ON, al-
though these studies did not control for the number of
previous ON episodes, optic nerve signal transmission,
and neuroaxonal retinal atrophy [21, 33, 34]. In a re-
cently published analysis of the relapse recovery of chil-
dren versus adults with MS, the probability of
incomplete recovery increased 1.33-fold with each dec-
ade of life [39].
We propose that an active age-dependent neuroplasti-
city of the visual system, most likely at a cortical level,
may explain our findings. First, there is evidence for the
existence of immature neural visual circuits in children
enabling further development of visual acuity in child-
hood and adolescence [40]. Indeed, the HCVA of healthy
children up to the age of 8–10 years is inferior to that of
healthy adults, and the age of 6–8 years is widely ac-
cepted as a “sensitive period” for the development of
amblyopia [40–42]. Second, animal studies have shown
that contrast sensitivity is less promoted by retinal integ-
rity than by the maturation of visual circuits [43]. In
children, contrast sensitivity matures between the age of
8 and 19 [41]. Accordingly, visual system maturation is
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likely to be ongoing in our MOGADped cohort (mean age
10.3±3.7 years). Indeed, we observed only minimal differ-
ences in HCVA and LCVA between affected and non-
affected- MOGADped-ON eyes, regardless of the profound
neuroaxonal retinal atrophy. Third, a large functional mag-
netic resonance imaging (fMRI) study demonstrated a clear
association between fMRI activity in the lateral occipital
cortex (as a marker of early adaptive neuroplasticity) and
visual outcome in young adults (mean age 32 years) with
acute ON. Interestingly, the fMRI activity was the strongest
predictor of the visual outcome in this study and was also
independent of other structural or electrophysiological pa-
rameters at baseline or 12 months follow-up [44].
Given the heterogeneity of MOGAD, we cannot ex-
clude that age- or disease-dependent differences in the
MOGAD autoimmunity contribute to the noted differ-
ences in ON recovery. Indeed, the role of MOG-IgG in
disease pathogenesis is not clear, and the titer and epi-
tope specificity of MOG-IgG may drive distinct effects
during injury and recovery [34, 35]. Additionally, other
cellular mechanisms, including T cell and microglial re-
sponse, need to be further characterized [2, 14]. Never-
theless, in our cohorts, these immunologic variables did
not impact structural or electrophysiologic metrics.
Our study has several limitations. Due to the limited
dataset, the extent of visual impairment before the onset
of ON and at nadir remains unknown and cannot be
compared between the groups. Visual acuity was cor-
rected habitually, and there is no visual field or color vi-
sion data. In addition, our study lacks MRI data on the
extent and volume of optic nerve lesions and accom-
panying lesions in the post-geniculate visual pathways or
occipital cortex. A prospective study combining longitu-
dinal clinical data, OCT and neuro-imaging, visual field
data, electrophysiology, and fMRI would be important to
confirm our findings. Furthermore, studies in MS or
aquaporin-4-IgG-positive NMOSD are needed to clarify
if the demonstrated age-dependent VA improvement is
universal or disease-specific.
Conclusion
In summary, a comparison of pediatric and adult
MOGAD cohorts demonstrates age-dependent effects
on visual recovery after ON. Despite almost identical
neuroaxonal retinal atrophy, functional vision is notably
better in children than in adults. Age-dependent cortical
neuroplasticity seems to be the most plausible mechan-
ism explaining this dissociation. Future studies, combin-
ing precise analysis of the anterior and posterior visual
system, are needed to confirm the leading role of central
neuroplasticity in determining visual recovery after
MOGAD-ON. Identification of a functionally relevant
cutoff age for the visual recovery in MOGAD-ON could
be of high relevance for the prognosis and care.
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ON and MOGADadult-ON. Despite profound neuroaxonal retinal atrophy
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neuritis, SD standard deviation. Supplementary Table 4. Comparison of all
OCT and VEP measures as well as visual acuity between in ON- and non-
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ON eyes with a history of ON, MOGAD-NON eyes without history of ON,
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cient, p-value: significant results p < 0.05 are indicated in bold letters.
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